VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CAHCardinal Health, Inc.
$237.92$56.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCAHFinancials

Cardinal Health, Inc. (CAH) Financials

30Y historyFree accessUpdated daily

Operating margins remain severely constrained, fluctuating between 0.7% and 1.3% over the last ten quarters despite revenue growth reaching as high as 22.4% in 2026Q1.

CAH Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Sales/Revenue250.55B222.58B226.83B204.98B181.33B162.47B152.92B145.53B136.81B129.98B121.55B102.53B91.08B101.09B107.55B102.64B98.5B95.99B87.41B86.85B79.66B72.67B64.52B56.73B51.14B47.95B38.35B25.11B21.08B18.39B9.25B
Revenue Growth %12.8%-1.87%10.66%13.04%11.61%6.24%5.08%6.38%5.26%6.94%18.55%12.57%-9.9%-6.01%4.78%4.2%2.62%9.82%0.64%9.02%9.63%12.62%13.73%10.94%6.65%25.03%52.72%19.15%14.58%98.93%10.83%
Cost of Goods Sold241.32B214.41B219.41B198.1B174.84B155.69B146.05B138.7B129.63B123.43B115B96.82B85.92B96.17B103.01B98.48B94.72B92.24B83.63B81.61B74.85B68.21B59.88B52.25B47.09B44.34B35.25B22.25B18.6B16.16B8.43B
COGS % of Revenue-96.33%96.73%96.65%96.42%95.83%95.51%95.3%94.75%94.97%94.62%94.43%94.33%95.13%95.78%95.95%96.16%96.1%95.68%93.96%93.96%93.86%92.8%92.1%92.09%92.47%91.93%88.61%88.24%87.88%91.21%
Gross Profit9.23B8.17B7.41B6.89B6.48B6.78B6.87B6.83B7.18B6.54B6.54B5.71B5.16B4.92B4.54B4.16B3.78B5.53B5.63B5.25B5.28B5.01B4.74B4.51B4.05B3.61B3.13B2.82B1.11B956.2M747.8M
Gross Margin %3.68%3.67%3.27%3.36%3.58%4.17%4.49%4.7%5.25%5.03%5.38%5.57%5.67%4.87%4.22%4.05%3.84%5.76%6.45%6.04%6.63%6.89%7.35%7.95%7.91%7.53%8.17%11.24%5.25%5.2%8.09%
Gross Profit Growth %-10.17%7.62%6.25%-4.34%-1.31%0.5%-4.83%9.73%0.02%14.55%10.68%4.88%8.37%9.11%10.09%-31.59%-1.91%7.41%-0.67%5.48%5.6%5.13%11.46%12.03%15.28%11.02%155.19%15.65%27.87%53.96%
Operating Expenses6.92B5.89B6.17B6.12B7.09B6.31B10.97B4.77B7.05B4.42B4.08B3.55B3.28B3.92B2.75B2.65B2.47B2.46B2.38B3.87B2.97B2.68B2.31B2.3B2.21B2.12B1.82B1.82B1.62B1.51B518.9M
OpEx % of Revenue-2.65%2.72%2.99%3.91%3.88%7.17%3.28%5.16%3.4%3.36%3.46%3.6%3.88%2.56%2.58%2.51%2.56%2.73%4.46%3.73%3.68%3.58%4.05%4.33%4.43%4.73%7.24%7.69%8.23%5.61%
Selling, General & Admin5.99B5.38B5B4.8B4.51B4.53B4.57B4.48B4.6B3.77B3.65B3.24B3.03B2.88B2.68B2.59B2.35B3.44B3.41B3.08B3.2B2.86B2.35B2.23B2.07B2B1.63B1.56B567.8M513.6M433.3M
SG&A % of Revenue-2.42%2.2%2.34%2.49%2.79%2.99%3.08%3.36%2.9%3%3.16%3.32%2.84%2.49%2.53%2.38%3.58%3.91%3.55%4.02%3.94%3.64%3.93%4.06%4.17%4.24%6.23%2.69%2.79%4.69%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses3M511M1.17B1.32B2.58B1.77B6.39B294M2.46B649M436M311M248M1.05B72M120M77M126.6M44.1M789.3M86.3M179.8M43.7M48.9M138.6M173.8M106.2M238.2M218.4M209.1M39.5M
Operating Income2.31B2.27B1.24B752M-607M472M-4.1B2.06B126M2.12B2.46B2.16B1.89B996M1.79B1.51B1.31B1.29B1.39B1.37B1.84B1.78B2.33B2.19B1.83B1.49B1.28B1.04B858.1M715.7M293.8M
Operating Margin %0.92%1.02%0.55%0.37%-0.33%0.29%-2.68%1.42%0.09%1.63%2.02%2.11%2.07%0.99%1.67%1.47%1.33%1.34%1.59%1.58%2.32%2.45%3.61%3.85%3.59%3.1%3.34%4.15%4.07%3.89%3.18%
Operating Income Growth %-83.02%65.29%223.89%-228.6%111.52%-298.93%1534.92%-94.06%-13.79%13.79%14.64%89.26%-44.42%18.36%15.84%1.52%-7.54%1.36%-25.54%3.52%-23.53%6.57%19.26%23.31%16.13%22.88%21.44%19.9%143.6%14.86%
EBITDA3.17B3.06B1.95B1.44B85M1.25B-3.19B3.06B1.16B2.84B3.1B2.61B2.34B1.39B2.12B1.83B1.56B1.51B1.61B1.7B2.14B2.08B2.62B2.45B2.08B1.77B1.54B1.28B1.08B924.8M333.3M
EBITDA Margin %1.26%1.38%0.86%0.7%0.05%0.77%-2.08%2.1%0.85%2.18%2.55%2.55%2.57%1.38%1.97%1.78%1.58%1.58%1.84%1.95%2.69%2.86%4.06%4.32%4.06%3.69%4.01%5.1%5.11%5.03%3.6%
EBITDA Growth %4.8%56.94%35.25%1598.82%-93.23%139.4%-204.08%164.25%-59.18%-8.48%18.68%11.43%68.27%-34.2%15.87%17.04%3.16%-6.15%-4.92%-20.85%3.11%-20.7%6.82%18.08%17.51%14.97%20.09%18.93%16.4%177.47%16.82%
D&A (Non-Cash Add-back)855M790M710M692M692M783M913M1B1.03B717M641M451M459M397M325M313M254M225.8M220M322.1M297.6M295.6M289.5M265.8M243.5M280.6M257M238.2M218.4M209.1M39.5M
EBIT2.19B2.32B1.25B747M-637M503M-3.53B2.04B101M2.13B2.45B2.11B1.93B1.01B1.79B1.61B1.32B1.41B1.44B1.52B1.92B1.91B2.41B2.33B1.97B1.49B1.28B1.04B858.1M715.7M293.8M
Net Interest Income-343M-215M-51M-84M-147M-180M-238M-294M-329M-201M-178M-141M-133M-123M-95M-93M-113M-114.4M-136.1M000000000000
Interest Income0000000000000000000000000000000
Interest Expense343M215M51M84M147M180M238M294M329M201M178M141M133M123M95M93M113M218.7M136.1M000000000000
Other Income/Expense-308M-174M-42M-89M-177M-149M326M-309M-354M-196M-183M-194M-87M-108M-94M4M-95M-127.6M-97.3M-121.4M-104.5M-117.8M-106.8M-106.3M-132.5M-154.9M-138.7M-256.8M-166.7M-176M-81.8M
Pretax Income2B2.1B1.2B663M-784M323M-3.77B1.75B-228M1.92B2.28B1.97B1.8B888M1.7B1.52B1.21B1.67B1.95B1.25B1.83B1.63B2.24B2.13B1.7B1.33B1.08B759.2M402.5M312.3M202.1M
Pretax Margin %0.8%0.94%0.53%0.32%-0.43%0.2%-2.47%1.2%-0.17%1.48%1.87%1.92%1.97%0.88%1.58%1.48%1.23%1.74%2.23%1.44%2.3%2.24%3.47%3.75%3.33%2.78%2.81%3.02%1.91%1.7%2.19%
Income Tax456M532M348M332M153M-289M-79M386M-487M630M845M755M635M553M628M552.1M624.6M524.2M633.9M412.6M577.1M586M706.7M699.5M575M474.8M424M302.9M242.9M204.9M94.4M
Effective Tax Rate %22.75%25.32%28.98%50.08%-19.52%-89.47%2.09%22.04%213.6%32.74%37.13%38.38%35.32%62.27%36.98%36.36%51.55%31.45%32.51%32.95%31.45%35.97%31.57%32.89%33.8%35.64%39.34%39.9%60.35%65.61%46.71%
Net Income1.56B1.56B852M330M-938M611M-3.69B1.36B256M1.29B1.43B1.22B1.17B334M1.07B959M642.2M1.15B1.3B1.93B1B1.05B1.47B1.41B1.06B857.4M679.7M456.3M247.1M181.1M111.9M
Net Margin %0.62%0.7%0.38%0.16%-0.52%0.38%-2.42%0.94%0.19%0.99%1.17%1.19%1.28%0.33%0.99%0.93%0.65%1.2%1.49%2.22%1.26%1.45%2.29%2.48%2.07%1.79%1.77%1.82%1.17%0.98%1.21%
Net Income Growth %0.06%83.22%158.18%135.18%-253.52%116.54%-370.95%432.42%-80.12%-9.74%17.45%4.2%249.1%-68.76%11.47%49.33%-44.23%-11.46%-32.65%93.09%-4.82%-28.74%4.89%33.1%23.19%26.14%48.96%84.66%36.44%61.84%31.65%
Net Income (Continuing)1.55B1.57B853M331M-937M612M-3.69B1.36B259M1.29B1.43B1.21B1.16B335M1.07B966M587M758.2M847.2M839.7M1.16B1.07B1.52B1.38B1.13B857.4M717.8M481M448.5M334.8M117.6M
Discontinued Operations000000000003M3M00008.8M-15.3M1.09B00000000000
Minority Interest160M147M1M1M3M3M3M2M020M17M00000000000000000000
EPS (Diluted)6.616.453.451.26-3.342.08-12.604.530.814.034.323.623.380.973.062.721.773.183.574.772.332.413.353.032.331.851.581.121.020.820.51
EPS Growth %2.03%86.96%173.81%137.72%-260.58%116.51%-378.15%459.26%-79.9%-6.71%19.34%7.1%248.45%-68.3%12.5%53.67%-44.34%-10.92%-25.16%104.72%-3.32%-28.06%10.56%30.04%25.95%17.09%41.07%9.8%24.39%60.78%-17.74%
EPS (Basic)-6.483.481.26-3.342.09-12.604.540.824.064.363.663.420.983.102.751.793.223.634.892.382.443.393.082.371.901.611.151.050.840.51
Diluted Shares Outstanding236M242M247M262M279M294M293M301M315M320M330M335M345M344M349M352.5M361.4M361.5M364M404.7M428.5M435.98M429.91M453.83M453.3M463.46M454.3M427.8M416.85M238.4M230.59M
Basic Shares Outstanding235M241M245M261M279M292M293M300M313M317M327M332M341M341M345M348.6M358.8M357.6M358.2M394.9M421.2M430.61M424.84M446.46M445.65M451.26M445.84M416.55M406.8M233.73M230.59M
Dividend Payout Ratio-31.65%58.57%159.09%-93.78%-42.33%226.95%44.8%35.88%37.86%35.59%105.69%28.06%28.59%39.41%17.4%13.31%7.48%10.18%4.92%3.55%3.19%4.26%4.27%4.41%12.43%4.65%5.02%6.79%

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Margin compression from pricing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Volatility Masks Underlying Trends

As reported in recent financial filings, Cardinal Health's revenue growth has fluctuated significantly, reaching a peak of 22.4% in 2026Q1 before decelerating to 11.0% by 2026Q3, reflecting the inherent volatility of a high-volume distribution model heavily reliant on pharmaceutical supply chain throughput and contract timing.

The wide swings in quarterly revenue growth suggest that the company's top-line performance is highly sensitive to the timing of large-scale contract renewals and shifts in pharmaceutical demand. Investors should monitor whether this growth remains sustainable or if it is merely a byproduct of inflationary pricing pass-throughs rather than genuine volume expansion.

Structural Constraints Limit Margin Expansion

Based on the company's reported income statements, gross margins have remained compressed within a narrow 3.1% to 4.1% range, underscoring the structural difficulty of achieving meaningful profitability in a low-margin, high-volume distribution environment where pricing power is largely dictated by manufacturers and healthcare payers.

The persistent inability to expand gross margins beyond the low single digits suggests that the company lacks the leverage to offset rising logistical costs. This margin profile warrants investigation into whether the 'Medical 2.0' initiative can actually drive a shift toward higher-margin products or if the business is permanently tethered to its current low-margin distribution model.

Operating Efficiency Remains Under Pressure

According to the provided quarterly data, operating margins have struggled to maintain momentum, hovering between 0.7% and 1.3%, which indicates that SG&A expenses are scaling in lockstep with gross profit, thereby preventing any significant operating leverage from materializing during periods of revenue growth.

The lack of operating margin expansion suggests that the company's cost structure is largely fixed and difficult to optimize. This implies that any future earnings growth will likely be dependent on top-line expansion rather than internal cost efficiencies, which may limit the company's ability to navigate potential economic downturns.

Stock-Based Compensation Distorts Earnings Clarity

As indicated by the latest quarterly filings, stock-based compensation has surged to $129 million in 2026Q3, a significant increase from the $30 million levels observed in early 2025, which raises questions regarding the quality of reported net income and the alignment of management incentives with shareholder value.

The sharp rise in stock-based compensation appears to be diluting the quality of earnings, as it represents a growing non-cash expense that impacts the bottom line. Investors should scrutinize whether this increase in compensation is tied to performance metrics that truly reflect operational success or if it is merely an escalating overhead cost.

CAH — Frequently Asked Questions

Quick answers to the most common questions about buying CAH stock.

What was Cardinal Health, Inc.'s (CAH) revenue in 2025?

For fiscal year 2025, Cardinal Health, Inc. (CAH) reported total revenue of $222.58B. This represents a 2307.2% increase compared to $9.25B in 1996.

Is Cardinal Health, Inc. (CAH) profitable?

Cardinal Health, Inc. (CAH) is profitable, generating $1.56B in net income for the fiscal year ending 2025 with a net profit margin of 0.7%.

What is Cardinal Health, Inc.'s operating profit margin?

Cardinal Health, Inc. (CAH) reported an operating income of $2.27B, resulting in an operating profit margin of 1.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Cardinal Health, Inc.'s gross profit and gross margin?

Cardinal Health, Inc. (CAH) generated $8.17B in gross profit for the year, representing a gross profit margin of 3.7%. This demonstrates the company's core pricing power and production efficiency.